Excavating novel diagnostic and prognostic long non-coding RNAs (lncRNAs) for head and neck squamous cell carcinoma: an integrated bioinformatics analysis of competing endogenous RNAs (ceRNAs) and gene co-expression networks

Liu Yang\textsuperscript{a}, Pingan Lu\textsuperscript{b}, Xiaohui Yang\textsuperscript{a}, Kaiguo Li\textsuperscript{a}, Xuxia Chen\textsuperscript{a}, and Song Qu\textsuperscript{a,c}

\textsuperscript{a}Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China; \textsuperscript{b}Faculty of Medicine, Amsterdam UMC, Univ of Amsterdam, Amsterdam, Netherlands; \textsuperscript{c}Key Laboratory of High-Incidence Tumor Prevention & Treatment, Ministry of Education, Guangxi Medical University, Nanning, China

\textbf{ABSTRACT}

Long non-coding RNAs (lncRNAs) have been demonstrated to fine-tune gene regulations that govern a broad spectrum of oncogenic processes. Nonetheless, our understanding of the roles of lncRNAs and their interactions with miRNAs and mRNAs in HNSCC is still highly rudimentary. Here, we present a comprehensive bioinformatics analysis in which competing endogenous RNA (ceRNA) network construction and weighted gene co-expression network analysis (WGCNA) were combined to explore novel diagnostic and prognostic lncRNAs for HNSCC. Differentially expressed miRNAs (DEGs), miRNAs (DEMs) and lncRNAs (DELs) were identified based on the RNA sequencing data and clinical data retrieved from TCGA database. LncRNA-regulated ceRNA networks were constructed based on the interactive RNA pairs predicted by miRDB, miCode and TargetScan. WGCNA was conducted to identify lncRNAs that were significantly correlated with patient overall survival (OS) and HNSCC tumor. RT-qPCR was employed to validate the expression of lncRNAs in HNSCC cell lines and patient sera. A ceRNA network consisting of 90 DEGs, 7 DEMs and 67 DELs associated with clinical traits was established. WGCNA and Kaplan-Meier survival analysis revealed that 5 DELs (MIR4435-2HG, CASC9, LINCO1980, STARD4-AS1 and MIR99AHG) were significantly correlated with OS of HNSCC patients, whereas DEL PART1 was most significantly correlated with the HNSCC tumor. The in silico predicted expression patterns of PART1, LINCO1980 and MIR4435-2HG were further validated in HNSCC cell lines and patient sera. Collectively, the present study provided novel insights into the lncRNA-regulated ceRNA networks in HNSCC and identified novel lncRNAs that harbor diagnostic and prognostic potentials for HNSCC.

\textbf{Abbreviations} BP, biological process. CC, cellular component. ceRNA, competing endogenous RNA. DEG, differential expressions of mRNA. DEL, differentially expressed lncRNA. DEM, differentially expressed miRNA. ESCC, esophageal squamous cell carcinoma. FPKM, Fragments Per Kilobase Million. GO, Gene Ontology. GS, gene significance. HNSCC, head and neck squamous cell carcinoma. KEGG, Kyoto Encyclopedia of Genes and Genomes. LncRNA, long non-coding RNA. MCC, Maximal Clique Centrality. ME, module eigengenes. MF, molecular functions. MM, module membership. MRE, miRNA-binding site. MYOSA, Myosin-Va. PART1, prostate androgen-regulated transcript 1. RBM3, RNA-binding motif protein 3. TCGA, The Cancer Genome Atlas. TOM, topological overlap measure. TSCC, tongue squamous cell carcinoma. WGCNA, weighted gene co-expression network analysis.

\textbf{Introduction}

As the sixth most common cancer worldwide, head and neck squamous cell carcinoma (HNSCC) is a malignant neoplasm of epithelial origin that often occurs in the nasopharynx, oropharynx, laryngo-pharynx, and neck\cite{1}. The disease is prevalent in South and Southeast Asia, accounting for an average of 550,000 new cases and more than 300,000 deaths annually \cite{2}. HNSCC patients with early-stage disease have a favorable prognosis after curative surgical resection combined with postoperative adjuvant radiotherapy. However, due to the subclinical nature of HNSCC in its initial stages, more than 60% of the
patients present with locally advanced disease at detection, which is associated with a poor 5-year overall survival rate of less than 50% [3,4]. Excavating novel biomarkers with good diagnostic potential is therefore of considerable importance for clinical outcomes of HNSCC patients. In addition, patients with advanced disease generally require multimodal treatments, and appropriate treatment decisions are critical for the survival of these patients [5,6]. Nonetheless, there is currently a lack of prognostic biomarkers with sufficient robustness and accuracy to guide tailoring current treatment modalities for individual patients [4].

Accumulating evidence has demonstrated that long non-coding RNAs (lncRNAs) play a crucial role in the pathogenesis and progression of a wide array of malignant diseases [7], which underscores the great potential of lncRNAs as a new class of cancer biomarkers and as attractive therapeutic targets for anti-cancer therapies. LncRNA is defined as an RNA transcript that is more than 200 nucleotides in length and does not overlap with the annotated coding gene [8]. Classical lncRNAs have similar structures to that of mRNAs, with 5′-ended m7G caps and 3′-ended poly(A) tails [8]. Initially, LncRNAs were regarded as ‘junk genes’. However, with the development of high-throughput sequencing technologies, many lncRNAs have been functionally characterized, participating in a broad spectrum of physiological and pathological processes such as cell cycle regulation, malignant transformation, proliferation signaling, apoptosis and invasion and metastasis of cancer cells [9–11]. Furthermore, mounting evidence has indicated that lncRNAs are capable of modulating epigenetic mechanisms, such as chromatin remodeling and histone modification [9,12,13].

A pivotal advance in understanding lncRNA biology is the competing endogenous RNA (ceRNA) theory, first postulated by Salmena et al. in 2011 [14]. These investigators proposed that lncRNAs contain miRNA-binding sites (MREs) that could function as molecular sponges to sequester miRNAs, thereby fine-tuning miRNA-regulated mRNA expressions [14] and ultimately contributing to cancer development [15,16].

Weighted gene co-expression network analysis (WGCNA) is a widely used in silico method that aims to identify co-expressed gene modules and to investigate the correlation between a specific gene network and the phenotype of interest [17]. WGCNA focuses on genome-wide information, constructs co-expression modules using hierarchical clustering, and can identify biologically relevant associations between modules and phenotypes of cancer [17,18].

The aim of this study is to explore novel lncRNA biomarkers with diagnostic and prognostic values for HNSCC by combining ceRNA network analysis with WGCNA, based on The Cancer Genome Atlas (TCGA) database [19]. A lncRNA-miRNA-mRNA interactive ceRNA network was constructed with the significantly differentially expressed RNAs, and the top-ranked hub RNAs of this network were subjected to the construction of a ceRNA subnetwork. Functional enrichment analyses were conducted to study the biological processes and pathways in which the differentially expressed RNAs were enriched. The diagnostic and prognostic value of the lncRNAs were analyzed with WGCNA and Kaplan-Meier survival analysis, and the expression patterns of three eligible candidate lncRNAs (PART1, MIR4435-2HG and LINC01980) were further validated in HNSCC cell lines and patient sera. Collectively, this study identified a set of differentially expressed lncRNAs with diagnostic and prognostic values for HNSCC and constructed novel ceRNA networks in HNSCC which may shed light on the mechanism underlying the development and progression of the disease.

Materials and methods

Data collection and processing

The RNA sequencing data, miRNA sequencing data and the corresponding clinical data of HNSCC patients were retrieved from TCGA data repository (https://portal.gdc.cancer.gov) [20], which contained 519 HNSCC tissues and 44 adjacent normal tissues. All RNA-seq data were open data whose protocols comply with TCGA guidelines and require no further ethical approval. GDCRNATools package and DT package in R [21] (version 3.6.1) were used to read the raw data and remove repetitive samples. The data were then subjected to background correction using EdgeR package [22] in R.
Identification and validation of differentially expressed mRNAs, miRNAs and lncRNAs

Limma package [22] was used to identify differentially expressed mRNAs (DEGs), differentially expressed miRNAs (DEM)s and differentially expressed lncRNA (DEls) between HNSCC tissues and adjacent normal tissues. A gene was considered differentially expressed when the FDR value was less than 0.01 (FDR < 0.01) and the fold change (FC) is greater than 1 (|log2 (FC)| > 1).

Gene Expression Profiling and Interactive Analyses (GEPIA, http://gepia.cancer-pku.cn) is an interactive web-based tool for analyzing RNA sequencing data of tumors and normal tissues from TCGA and genotype-tissue expression (GTex) database [23,24]. GEPIA database was used to validate the expression of key RNAs in the constructed ceRNA networks between HNSCC and non-HNSCC normal tissues. Genes with |log₂(FC)| > 1 and p-value < 0.05 were considered statistically significant.

Construction of lncRNA-miRNA-mRNA networks

The lncRNA-miRNA-mRNA network was constructed in three steps. First, miRcode [25] (http://www.mircode.org) database and StarBase database [26] (version 2.0, http://starbase.sysu.edu.cn) were used to predict interacting DEL-DEM pairs. Next, the corresponding target genes of the predicted DEMs were retrieved from miRDB and TargetScan [27], after which the intersection was taken between the retrieved target genes and the previously identified DEGs. Finally, Cytoscape (version 3.6.1) [28] was used to visualize the ceRNA networks. The network diagram visually displayed the relationships between DELs, DEMs and DEGs, with each node representing a different RNA molecule and each edge representing the interaction between two linked nodes. The top 10 hub RNAs were selected from the constructed ceRNA network for the construction of a ceRNA subnetwork using the plugin Cyto-Hubba [29].

WGCNA

A weighted gene co-expression network associated with clinical traits was constructed using WGCNA package based on R [17]. Outliers were first excluded via sample clustering. A soft threshold was then applied to determine the weight of the edges between genes and to merge individual genes into gene modules. By setting 3 as the soft threshold, a weighted co-expression network was established using WGCNA package, which was a scale-free topology network. Subsequently, the gene modules were identified using the methods of Fragments Per Kilobase Million (FPKM) and topological overlap measure (TOM) [30]. To avoid generating too many modules, dynamic tree cutting algorithm [31] was used to merge modules. A minimum height of 0.6 and a minimum module size (minModuleSize) of 30 were used as cutoff values. Ultimately, the lncRNA modules that statistically significantly correlated with patient survival were selected as the modules of interest for further analysis.

Functional enrichment analysis

Gene Ontology (GO) [25] and Kyoto Encyclopedia of Genes and Genomes (KEGG) [32] were used to study the biological processes (BP), cellular components (CC), molecular functions (MF) and pathways of the total identified DEGs and DEGs in the constructed ceRNA network. Using the R package clusterProfiler [33] and pathview [34], GO terms or KEGG pathways with an adjusted p-value < 0.05 were considered statistically significantly enriched.

Survival analysis

Kaplan-Meier survival analysis [35] was performed to investigate the relationship between the expression of DELs and OS of HNSCC patients. The constructed ceRNA network was first combined with clinical data of HNSCC patients. The ggplot2 package [31] in R was used to generate Kaplan-Meier survival curves to evaluate the relationship between OS and the expression levels of DEGs, DEMs and DELs.

Cell lines and blood samples

The nasopharyngeal carcinoma cell line CNE-2 was purchased from the Fudan University
Shanghai Cancer Center. The nasopharyngeal carcinoma cell line C666-1, human oral keratinocytes (HOK) cell line and SCC-4 oral squamous cell carcinoma (OSCC) cell line were provided by the Experimental Center of Guangxi Medical University. The immortalized nasopharyngeal epithelial cell line NP69 was kindly provided by Professor S.W. Tsao, University of Hong Kong. The blood samples were collected from 10 patients with primary HNSCC hospitalized in Guangxi Medical University Cancer Hospital (Guangxi, China) from July 2020 to April 2021. These patients included 4 cases of oral squamous cell carcinoma, 2 cases of oropharyngeal squamous cell carcinoma, 3 cases of hypopharyngeal squamous cell carcinoma and 1 case of laryngeal squamous cell carcinoma. The blood samples of another 10 normal individuals were collected at Guangxi Medical University Cancer Hospital during the same period, which constituted the control group. All enrolled patients were diagnosed as primary HNSCC by pathological diagnosis and had not undergone any previous treatment. Patients with other malignancies were excluded. The study protocol was approved by the Ethics Committee of the Affiliated Cancer Hospital of Guangxi Medical University. All patients and their guardians were informed and signed the informed consent form.

**Cell culture**

HOK cells were cultured in Oral Keratinocyte Medium (OKM, ScienCell Research Laboratories, Carlsbad, CA, USA). NP69 cells were cultured in keratinocyte serum-free medium (Defined Keratinocyte-SFM, Gibco, Carlsbad, CA). CNE-2, C666-1 and SCC-4 cells were cultured in DMEM medium (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100μg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO₂.

**Verification of the hub RNAs using RT-qPCR**

The hub RNAs PART1, MIR4435-2 HG and LINC01980 were selected from the ceRNA network and subjected to RT-qPCR analysis to verify the reliability of the bioinformatics findings. The intracellular expression levels of PART1, MIR4435-2 HG and LINC01980 and their expression levels in serum were determined using RT-qPCR. Total cellular RNA was extracted using TrizolTM reagent (Takara, Dalian, Japan). Total serum RNA was extracted using miRcute Serum/Plasma miRNA isolation kit (DP160526, Tiangen Biotech, China). Total RNA was reversely trancribed into cDNA following the manufacturer’s instructions of MightyScript First Strand cDNA Synthesis Master Mix reagent kit (B639251, Sango Biotech, China). The 2X SG Fast qPCR Master Mix kit was employed, and spectrophotometer was used to determine the Ct value for each sample. GAPDH expression was measured and served as endogenous control. The measurement was repeated 3 times (n = 3) for each sample, and the data was analyzed using the 2^−ΔΔct method. The following primer sequences were used: (5’3’): MIR4435-2 HG-F: AGGAGGCAGGAGCATGGAACCTC, MIR4435-2HG-R: CAGGGGAAGGCGATCTCATACACATC, LINC01980-F: CATTGGAGGTGCGGTTGACTTC, LINC01980-R: CACTAACCAGGTCGACAGCTAC, PA RT1-F: CCAGAGCCAGCAGTCACTTAGC, PA RT1-R: TGTTGTCCAGTGCAGGCTTT.

**Statistical analysis**

R software was used for all data analysis and processing. Independent t-test and ANOVA were used for continuous variables. Pearson’s chi-square test was used for categorical variables. Kaplan-Meier method was used for survival analysis. P < 0.05 was considered statistically significant. Benjamini–Hochberg procedure for multiple testing and false discovery rate (FDR) were used to correct the p-values for the selection of differentially expressed mRNAs, miRNAs and lncRNAs.

**Results**

In this study, a lncRNA-miRNA-mRNA ceRNA network consisting of 90 DEGs, 67 DELs and 7 DEMs was constructed based on RNA-seq data of HNSCC from the TCGA database. WCGNA was then conducted to identify the co-expression modules of HNSCC-related lncRNAs and their associations with clinical traits. After intersecting the
survival-related co-expression module with the constructed ceRNA network, the top five most significant survival-related lncRNAs (MIR4435-2HG, CASC9, LINC01980, STARD4-AS1, MIR99AHG) were yielded. Besides, lncRNA (PART1) showed the most significant correlation with HNSCC tumor. The expressions of PART1, MIR4435-2HG and LINC01980 were validated in nasopharyngeal carcinoma cell lines, oral squamous cell carcinoma cell lines and the sera of HNSCC patients using RT-qPCR assays.

**Differentially expressed mRNA, miRNA and lncRNA in HNSCC**

According to the |log2 FC|>1 and FDR<0.01 cutoff criteria, a total of 1998 DEGs (1170 down-regulated, 828 up-regulated), 80 DEMs (33 down-regulated, 47 up-regulated), and 1019 DELs (296 up-regulated, 723 down-regulated) were identified from 519 HNSCC tissue samples and 44 non-HNSCC normal tissues from the TCGA database. The distributions of DEGs, DEMs and DELs were visualized using volcano plots (Figure 1(a)). Additionally, the top 5 most statistically significant DEGs, DEMs and DELs were summarized in Table 1 and indicated with arrows in Figure 1(a). Notably, all these most significantly differentially expressed genes were downregulated in HNSCC tissues compared to non-HNSCC normal tissues (Table 1). Furthermore, the expression levels of DEGs, DEMs and DELs between HNSCC tissues and non-HNSCC normal tissues were visualized using heatmap (Figure 1(b)). The lncRNA-mRNA pair with the strongest correlation (R = 0.567, P = 5.81e-48) was identified using Pearson correlation analysis and the relationship between their expression levels in HNSCC and normal tissues was plotted in Figure 2.

**Functional analysis of the DEGs**

To obtain a global picture of the biological functions of the identified DEGs in HNSCC, GO and KEGG enrichment analyses were performed for the above identified 1998 DEGs. The top 10 most significant (p < 0.01) GO terms (BPs, CCs and MFs) and the top 10 most significantly (p < 0.01) enriched KEGG pathways were displayed in Figure 3. It is noteworthy that the analyzed DEGs were enriched in extracellular matrix organization and collagen catabolic process, which are biological processes potentially associated with cancer cell invasion and migration. Enriched CC terms indicated that the DEGs were mainly concentrated in muscle components and in extracellular regions. MF terms such as sequence-specific DNA binding and calcium ion binding indicated the potential functions of the DEGs in gene regulation and signal transduction. KEGG pathway analysis further detected several well-known cancer-associated pathways including focal adhesion, ECM-receptor interaction and calcium signaling pathways.

**Construction of lncRNA-miRNA-mRNA ceRNA networks**

From the previously obtained 80 DEMs and 1019 DELs, 136 pairs of interacting lncRNAs (including 67 HNSCC-specific DELs) and miRNAs (including 7 HNSCC-specific DEMs) were identified using miRcode database and StarBase database. MiRDB and TargetScan databases were used to predict the target genes of the 7 HNSCC-specific DEMs, and the overlap between these genes and the previously identified 1998 DEGs was analyzed, yielding 90 overlapping DEGs in total. Then, a lncRNA-miRNA-mRNA interactive ceRNA network consisting of the overlapping 90 DEGs, 67 HNSCC-specific DELs and 7 HNSCC-specific DEMs was constructed and visualized using Cytoscape (Figure 4(a)). GO and KEGG enrichment analyses were performed to investigate the biological functions of the 90 DEGs in the ceRNA network. As shown in Figure 5(a), the construction of ceRNA network has filtered out a large proportion of genes not related to cancer, as more cancer-related BPs and MFs were detected by the GO enrichment analysis. These cancer-related processes and functions included the regulation of cellular response to growth factor stimulus, positive regulation of cell proliferation, receptor binding, heparin binding and growth factor activity (Figure 5(a,c)). Extracellular region was still indicated as the predominant location where the DEGs exert their biological functions (Figure 5(b)). Moreover, KEGG enrichment results
demonstrated that the DEGs were significantly enriched in the AMPK signaling pathway (Figure 5(d)), which is a well-established regulatory pathway of cellular energy homeostasis that is frequently dysregulated in tumor cells. Subsequently, the top 10 hub RNAs with the highest Maximal Clique Centrality (MCC) scores were identified using the CytoHubba plugin of Cytoscape (Table 2), which consisted of 3 DEMs, 5 DELs and 1 DEG. These hub RNAs were then used for the construction of a ceRNA subnetwork, as shown in Figure 4(b). In this subnetwork, IncRNA PART1 and LINC00520 exhibited the most significant differential expression in
HNSCC tissues compared to non-HNSCC normal tissues. The expression analysis based on GEPIA database showed that PART1 was significantly downregulated and LINC00520 was significantly upregulated in HNSCC tissues (Figure 4(c)), which were consistent with the results obtained in this study (Table 2).

**Weighted gene co-expression network analysis of IncRNAs**

To identify the gene modules that are significantly correlated with overall survival (OS) of HNSCC patients, a co-expression network of the top 60% variance IncRNAs was constructed using WGCNA algorithm. Hybrid hierarchical clustering based on the topological overlaps was generated using the Dynamic Tree Cut method (Figure 6(a)). By setting the power (β) = 3 as soft threshold and comparing the Pearson’s correlation coefficients (PCC), 24 co-expression modules of IncRNAs associated with clinical traits were identified (Figure 6(b)). Among them, the gray module consisted of genes that were not co-expressed and was therefore not included in further analysis. Of note, the brown module showed the most significant correlation with the survival of HNSCC patients (R = 0.17, P = 5e−05). The correlation between module membership (MM) in the brown module and gene significance (GS) for survival was shown in Figure 6(c). To further compare the similarity of co-expression levels, the modules were clustered according to the correlation with module eigenvalues (MEs) (Figure 6(d)). Finally, the IncRNAs in the brown module were intersected with the 67 differentially expressed IncRNAs in the constructed ceRNA network to ascertain the prognostic value of IncRNAs in the constructed ceRNA network, and to filter out all survival-related IncRNAs that were also significantly differentially expressed in HNSCC tissues. Notably, 5 survival-related IncRNAs from the brown module were also found in the ceRNA network (Table 3), which were subsequently subjected to Kaplan-Meier survival analysis. Moreover, IncRNA PART1 from the purple module exhibited the most significant correlation with HNSCC (p.GS.tumor = 3.69E-33) (Table 3) across all modules in the co-expression network and was also present in the previously constructed ceRNA network and subnetwork.

**Verification of the prognostic values of IncRNAs**

To evaluate the prognostic value of the constructed ceRNA network, the 5 IncRNAs (MIR4435-2HG, CASC9, LINC01980, STARD4-AS1, MIR99AHG) with the strongest correlation with the survival of HNSCC patients (Table 3) were subjected to Kaplan-Meier survival analysis. The survival curves of the 5 IncRNAs were shown in Figure 7. Among the analyzed genes, patients overexpressing MIR4435-2HG, LINC01980, and CASC9 showed a significantly decreased overall survival (p < 0.05), whereas patients carrying

| Symbol     | Type   | logFC | FDR     | P-value  | Expression pattern |
|------------|--------|-------|---------|----------|--------------------|
| SLC8A1-AS1 | IncRNA | −5.177| 3.39E-181| 4.54E-185| Down               |
| LINC01829  | IncRNA | −5.894| 4.63E-155| 1.24E-158| Down               |
| IL12A-AS1  | IncRNA | −4.144| 1.08E-135| 4.36E-139| Down               |
| AC005165.1 | IncRNA | −5.235| 6.18E-99 | 3.31E-102| Down               |
| AC027130.1 | IncRNA | −4.757| 1.19E-96 | 7.98E-100| Down               |
| CST2       | mRNA   | −9.984| 1.14E-281| 6.32E-286| Down               |
| PM20D1     | mRNA   | −6.545| 5.81E-267| 6.44E-271| Down               |
| CA6        | mRNA   | −10.096| 5.11E-260| 8.50E-264| Down               |
| PRH1       | mRNA   | −9.217| 3.30E-247| 7.32E-251| Down               |
| CST4       | mRNA   | −11.020| 1.12E-245| 3.10E-249| Down               |
| hsa-mir-381| miRNA  | −3.387| 3.51E-103| 5.42E-106| Down               |
| hsa-mir-101-2| miRNA | −2.079| 6.05E-88 | 1.87E-90 | Down               |
| hsa-mir-101-1| miRNA | −2.077| 1.34E-87 | 6.20E-90 | Down               |
| hsa-mir-378c| miRNA  | −2.538| 7.49E-72 | 4.63E-74 | Down               |
| hsa-mir-299| miRNA  | −2.520| 7.11E-56 | 7.69E-58 | Down               |

FDR, false discovery rate. Log(FC), log fold change.

---

Table 1. Top 5 most significantly differentially expressed IncRNA, mRNA and miRNA.
overexpression of MIR99AHG and STARD4-AS1 exhibited a superior prognosis ($p < 0.05$). Furthermore, the expression of these 5 lncRNAs in HNSCC tissues and non-HNSCC normal tissues were validated using GEPIA database (Figure 8). While 4 out of 5 lncRNAs showed significant differential expression, the expression of STARD4-AS1 failed to reach statistical significance between tumor and normal tissues, probably due to changing the databases.

**Validation of gene expressions of diagnostic and prognostic DELs**

To verify the reliability of the bioinformatics findings, two survival-related DELs (MIR4435-2H and LINC01980) and the HNSCC-related DEL (PART1) were analyzed by RT-qPCR assays to validate their expression patterns. Consistent with our *in silico* findings, the expression of MIR4435-2H was upregulated and the expressions of PART1 and LINC0198 were downregulated in nasopharyngeal carcinoma cells (C666-1 and CNE-2) and OSCC cells (SCC-4) compared to their respective controls (HP69 and HOK) (Figure 8(a)). Similar expression patterns of the three DELs were further confirmed in the serum of HNSCC patients compared to normal individuals (Figure 8(b)). Collectively, the RT-qPCR results were in line with the above-described bioinformatics findings, thus confirming the validity and reliability of the bioinformatics analyses performed.

**Discussion**

Excavating novel diagnostic and prognostic biomarkers is a pressing need for the ambition of earlier detection of preneoplastic tumors and personalized treatment designs for HNSCC patients. Recent years, lncRNAs have drawn increasing attention and are considered as highly informative biomarkers in the oncology setting. According to the ceRNA hypothesis first founded by Salmena et al., lncRNAs can fine-tune numerous biological processes via modulating miRNA activities and the miRNA-regulated mRNA expression [14]. Mounting evidence has demonstrated that lncRNAs are not only inextricably associated with tumorigenic processes such as tumor cell

---

*Figure 2.* Scatter plot of the expression of lncRNA ZNF710-AS1 and mRNA GDP1L in HNSCC and normal tissues. The lncRNA-mRNA exhibited similar expression pattern in HNSCC tissues and non-HNSCC normal tissues and showed the strongest correlation in the Pearson correlation analysis of all the 1998 DEGs, 80 DEMs, 1019 DELs.
proliferation, invasion, migration and metastasis [7,36,37], but are also detectable in body fluids [38,39], making them a promising biomarker in reflecting the pathological status of the disease. Therefore, in this study, a series of bioinformatics approaches, including the construction and analysis of ceRNA networks, GO and KEGG enrichment analyses, WGCNA and Kaplan-Meier survival analyses, were integrated to systematically analyze the RNA-seq data of HNSCC samples from TCGA database for the sake of identifying novel cancer-related IncRNAs with diagnostic and prognostic potentials.

A total of 1998 DEGs, 80 DEMs and 1019 DELs were identified in HNSCC tissues. The DEGs were significantly enriched in several cancer-associated processes and pathways previously reported to be essential for the cancer invasion-metastasis cascade, such as collagen catabolic process [40], extracellular organization [41], focal adhesion and ECM-receptor interaction [40]. Further functional analyses of the 90 DEGs from the constructed ceRNA network revealed that the genes were crucially involved in sustaining the proliferative signaling of cancer cells. Moreover, KEGG enrichment results showed that the 90 DEGs were significantly enriched in the AMPK signaling pathway, which is a well-established cancer-related pathway essential for the survival of cancer cells under metabolic stress [42,43]. Apart from this, due to the strong correlation of these DEGs with other nodes within the ceRNA network, it is well-reasoned to speculate that miRNAs and IncRNAs in this network may also play a role in similar biological processes and pathways.

LncRNA PART1 (prostate androgen-regulated transcript 1) was originally considered as a tumor

![Figure 3. Functional analysis of the 1998 significantly differentially expressed mRNAs in HNSCC. (a-c) Top 10 most significantly enriched BP (a), CC (b), MF (c) terms of the differentially expressed mRNAs analyzed by GO enrichment analysis (p < 0.01). (d) Top 10 most significantly enriched KEGG pathways of the differentially expressed mRNAs (p < 0.01). BP, biological processes. CC, cellular components. MF, molecular functions. GO, gene ontology. KEGG, Kyoto Encyclopedia of Genes and Genomes.]
suppressor gene for prostate cancer due to its location on the chromosome 5q12.1\textsuperscript{45}. This chromosome region has been demonstrated to be associated with tumor-suppressive activities and was found to be deleted in prostate cancer cells and 39% of prostate cancer metastases analyzed \cite{44}. However, functional studies of some other solid malignancies have reported opposite findings suggestive for an oncogenic role of PART1. For example, recent in vitro observations indicated that silencing of PART1 substantially sensitized the response of TE1 and KYSE-450 esophageal squamous cell carcinoma (ESCC) cells to gefitinib, while upregulation of PART1 led to sequestering
of miR-129 and the resultant upregulation of Bcl-2, thereby conferring ESCC cells resistance to gefitinib [45]. Investigations in non-small cell lung cancer and colorectal cancer also showed that overexpression of PART1 markedly promoted tumor cell proliferation and epithelial–mesenchymal transition in vitro and accelerated tumor growth in mouse xenograft models in vivo [46,47]. By contrast, in the context of HNSCC, bioinformatics findings in tongue squamous cell carcinoma (TSCC) supported the tumor suppressive role of PART1, demonstrating that PART1 was downregulated in TSCC tissues and that high expression levels of PART1 were associated with a prolonged overall survival of TSCC patients [48,49]. Consistent with these results, in this study, PART1 was found to be a downregulated DEL in HNSCC tissues, and its differential expression exhibited the highest statistical significance among all genes in the ceRNA subnetwork. RT-qPCR data of HNSCC cell lines and the sera of HNSCC patients further confirmed the downregulated expression pattern of PART1 in HNSCC. Furthermore, miRNA hsa-mir-211, hsa-mir-206 and hsa-mir-31 showed a significant correlation with PART1 according to the ceRNA subnetwork. This provided novel clues about possible initial molecular events through which PART1 exerts its functions, and these miRNAs may therefore serve

Figure 5. Functional analysis of the 90 significantly differentially expressed mRNAs from the constructed ceRNA network. (a-c) Top 10 most significantly enriched BP (a), CC (b), MF (c) terms of the differentially expressed mRNAs analyzed by GO (p < 0.01). (d) Top 10 most significantly enriched KEGG pathways of the differentially expressed mRNAs (p < 0.01). BP, biological processes. CC, cellular components. MF, molecular functions. GO, gene ontology. KEGG, Kyoto Encyclopedia of Genes and Genomes.

Table 2. The top 10 hub RNAs in the ceRNA network ranked by MCC scores.

| Rank | Name          | RNA type | MCC score | Expression pattern |
|------|---------------|----------|-----------|--------------------|
| 1    | hsa-mir-211   | miRNA    | 102.6666667 | Down              |
| 2    | hsa-mir-31    | miRNA    | 92        | Up                 |
| 3    | hsa-mir-206   | miRNA    | 84.0166667 | Down              |
| 4    | RMST          | lncRNA   | 81.16,666,667 | Down            |
| 5    | DLX6-AS1      | IncRNA   | 79.75     | Up                 |
| 6    | HOTTIP        | IncRNA   | 79.25     | Up                 |
| 7    | ZFY-A51       | IncRNA   | 79.25     | Down              |
| 8    | PART1         | IncRNA   | 79.25     | Down              |
| 9    | SLC24A2       | mRNA     | 77.0833333 | Up                |
| 10   | LINC00520     | lncRNA   | 75.75     | Up                |

MCC, Maximal Clique Centrality.
as a starting point to dissect the mechanism of action of PART1 in HNSCC cells. Most importantly, PART1 showed the strongest correlation with HNSCC tumor across all co-expression
Table 3. Differentially expressed lncRNAs that were highly correlated with HNSCC and patient survival.

| Probes | moduleColor | GS. Tumor | p.GS. Tumor | GS. Survival | p.GS. Survival |
|--------|-------------|-----------|-------------|--------------|---------------|
| PART1  | purple      | −0.482    | 3.69E-33    | 0.054        | 0.206         |
| MIR4435-2HG | brown     | 0.216     | 3.41E-07    | −0.212       | 5.59E-07      |
| CASC9  | brown       | 0.182     | 1.89E-05    | −0.159       | 0.0001        |
| LINC01980 | brown     | 0.225     | 1.12E-07    | −0.117       | 0.006         |
| STARD4-AS1 | brown    | 0.183     | 1.75E-05    | 0.161        | 0.0002        |
| MIR99AHG | brown     | 0.083     | 0.043       | 0.172        | 4.83E-05      |

GS, gene significance.

modules constructed by WCGNA, suggesting its potential as a diagnostic biomarker to detect pre-neoplastic HNSCC earlier.

To further explore prognosis-related lncRNAs for HNSCC, intersection was taken between the survival-related brown co-expression module and the constructed ceRNA network, yielding a set of 5 survival-related DELs: MIR4435-2HG, CASC9, LINC01980, STARD4-AS1 and MIR99AHG. Kaplan-Meier survival analysis indicated that high expressions of MIR4435-2HG, LINC01980, and CASC9 and low expressions of STARD4-AS1 and MIR99AHG were correlated with a significantly reduced overall survival time of HNSCC patients. Therefore, these five lncRNAs can be considered to have prognostic values for the survival of HNSCC patients, and additional clinical evaluations are needed to further confirm their predictive power. In addition, RT-qPCR analysis of HNSCC cells and patient serum verified the overexpression of MIR4435-2HG or LINC01980.

A variety of cancers aberrantly express MIR4435-2HG; its overexpression has been observed in renal [50], gastric [51], colorectal [52], brain [53], ovarian [54], lung [55] and liver tumors [56] and has been functionally linked to a highly proliferative and invasive phenotype. Elevated MIR4435-2HG expression was also detected in TSCC cell lines CAL27 and SCC25, whereas knockdown of MIR4435-2HG attenuated its inhibition on miR-383-5p, leading to downregulation of RNA-binding motif protein 3 (RBM3) and an impaired cell proliferation and invasion [57]. The results in this study further corroborated that MIR4435-2HG was highly expressed in HNSCC tissues, cell lines and patient sera and is clinically associated with an inferior prognosis. Intriguingly, recent transcriptomics studies based on TCGA database showed that dysregulated MIR4435-2HG was closely associated with tumor cell glycolysis in hepatocellular carcinoma, mesothelioma, glioma, bladder carcinoma, pancreatic adenocarcinoma and uveal melanoma [56]. These new clues suggest that MIR4435-2HG could also act as an important regulator in deregulating cellular energetics, which is another hallmark of cancer [58]. However, to date, the function of MIR4435-2HG in glycolysis remained unexplored in HNSCC, and further functional studies are still urgently awaited to unravel the mechanistic basis underlying this in silico observation.

At present, there is very limited evidence for the implication of lncRNA LINC01980 in cancer, and its role in HNSCC has not been documented to date. Previous investigations in ESCC have detected a significantly elevated expression of LINC01980 in ESCC cell lines and patient-derived tissue specimens [59,60]. Observational follow-up data further demonstrated that LINC01980 overexpression was correlated with a decreased overall survival of ESCC patients [59,60]. Mechanistically, forced (over)expression of LINC01980 in ESCC cell lines has been shown to promote Myosin-Va (MYO5A) expression by inhibiting miR-190a-5p, resulting in enhanced tumor cell proliferation and EMT [59]. Upregulated expression and tumorigenic potential of LINC01980 has also been observed in hepatocellular carcinoma cell lines Huh7 and Hep3B [61]. In line with these findings, in this study, LINC01980 overexpression was detected in HNSCC tissues, cell lines and patient sera by bioinformatics approaches and RT-qPCR assays, which was also confirmed to be correlated with a significantly reduced overall survival time. The mechanistic rationale of LINC01980 in HNSCC still warrants further investigation, and the DEMs and DEGs in the constructed ceRNA network in this study may serve as an attractive starting point for these future functional studies.

In summary, this study successfully constructed a lncRNA-miRNA-mRNA interactive
ceRNA network for HNSCC and identified a set of IncRNAs with diagnostic and prognostic values for HNSCC patients. These identified IncRNAs may therefore hold the promise of further refining the accuracy and explanatory power of the existing diagnostic and prognostic tools. To the best of our knowledge, this is the first study to excavate novel diagnosis- or prognosis-related...
lncRNAs in HNSCC through constructing ceRNA networks combined with WGCNA. However, several limitations to the present study still need to be noted. First, the findings in this study were based on the TCGA database with pure in silico methods. Although some findings have been
validated by the GEPIA database and RT-qPCR analysis, additional confirmations using experimental methods are still needed. Second, the group of patients enrolled in this study is relatively small, and the cell lines used for validation did not cover all possible anatomical origins of HNSCC, suggesting that additional studies in larger patient cohorts and in more different HNSCC cell lines are needed to yield more conclusive data on the accuracy and robustness of the identified biomarker candidates. Nonetheless, translating these lncRNAs into clinical applications or developing novel therapeutic strategies targeting these lncRNAs both require future functional studies to elucidate the complete picture of their molecular mechanisms. The RNA interactions in the constructed ceRNA networks in this study may provide valuable hints to initiate these studies.

Conclusions

In summary, the in silico findings of our integrated bioinformatics analysis combining ceRNA network construction with WGCNA identified five differentially expressed lncRNAs (MIR4435-2HG, CASC9, LINC01980, STARD4-AS1 and MIR99AHG) with pronounced correlation with OS of HNSCC patients and one lncRNA (PART1) with a superior performance in discriminating HNSCC tissues from non-HNSCC normal tissues. The credibility of these computational findings was further confirmed by a series of RT-qPCR analyses, which detected similar expression patterns of PART1, MIR4435-2HG and LINC01980 in HNSCC cell lines and patient sera.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was supported by Guangxi Key Laboratory of Prevention and Treatment for RegionaHigh FrequencyTumor [GK2018-08, GKE2019-15, GKE-ZZZ202012, GKE-ZZZ202128]; the General Program of Guangxi Natural Science Foundation [2018GXNSFAA281032].

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics statement

This study was approved by the Ethics Committee of Guangxi Medical University Cancer Hospital, and all the patients provided their informed consent (reference number: LW2021061).

Author contribution

SQ designed the study, XY and LY conducted the study and performed data analysis, KL and XC provided analytics tools, LY prepared the figures and wrote the manuscript, PL contributed to figure generation, data interpretation, manuscript writing and English editing. All the authors have read and approved the final version of this article.

ORCID

Song Qu @ http://orcid.org/0000-0003-2784-6148

References

[1] Mehanna H, Paleri V, West CM, et al. Head and neck cancer–Part 1: epidemiology, presentation, and prevention. BMJ. 2010;341:c4684.
[2] Mandal R, Şenbabaoglu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1(17). DOI:10.1172/jci.insight.89829
[3] Lee NY, Ferris RL, Psysri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450–462.
[4] Braakhuis BJ, Brakenhoff RH, Leemans CR. Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors. Ann Oncol. 2012;23(Suppl 10):x173–177.

[5] Chow LQM. Head and neck cancer. N Engl J Med. 2020;382:60–72.

[6] Ang KK. Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes. The Oncologist. 2008;13(8):899–910.

[7] Huarte M. The emerging role of IncRNAs in cancer. Nat Med. 2015;21(11):1253–1261.

[8] Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2016;16(3):167–179.

[9] Hu Q, Ye Y, Chan L-C, et al. Oncogenic IncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nature Immunology. 2019;20(7):835–851.

[10] Xu Y, Wu J, Peng X, et al. LncRNA LINC00341 mediates PM(2.5)-induced cell cycle arrest in human bronchial epithelial cells. Toxicol Lett. 2017;276:1–10.

[11] Li T, Chen Y, Zhang J, et al. TUG1 promotes cells proliferation and inhibits cells apoptosis through regulating AURKA in epithelial ovarian cancer cells. Medicine (Baltimore). 2018;97(e12131). DOI:10.1097/MD.0000000000012131

[12] Xu H, Jiang Y, Xu X, et al. Inducible degradation of lncRNA Sros1 promotes IFN-γ-mediated activation of innate immune responses by stabilizing Stat1 mRNA. Nature Immunology. 2019;20(12):1621–1630.

[13] Luo H, et al. HOTTIP IncRNA promotes hematopoietic stem cell self-renewal leading to AML-like disease in mice. undefined, undefined (2019).

[14] Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta stone of a hidden RNA language? Cell. 2011;146(3):353–358.

[15] Qi X, Zhang D-H, Wu N, et al. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52(10):710–718.

[16] Ninomiya K, Adachi S, Natsume T, et al. LncRNA-dependent nuclear stress bodies promote intron retention through SR protein phosphorylation. EMBO J. 2019;39(3):e102729.

[17] Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9(1):559.

[18] van Dam S, Vösa U, van der Graaf A, et al. Gene co-expression analysis for functional classification and gene-disease predictions. Brief Bioinform. 2018;19(4):575–592.

[19] Blum A, Wang P, Zenklusen JG. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530.

[20] Tomczak K, Czerwińska P, Wiznowericz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–77.

[21] Li R, Qu H, Wang S, et al. GDCRNATools: an R/Bioconductor package for integrative analysis of lncRNA, miRNA and mRNA data in GDC. Bioinformatics. 2018;34(14):2515–2517.

[22] Law CW, Alhamdoosh M, Su S, et al. RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR. F1000Res. 2016;5:1408.

[23] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.

[24] Ardile KG, Deluca DS, Segrè AV, Human genomics. The Genotype-Tissue Expression (GTEX) pilot analysis: multitissue gene regulation in humans. Science. 2015;348(6235):648–660.

[25] Mi H, Muruganujan A, Ebert D, et al. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 2019;47(D1):D419–D426.

[26] Li JH, Liu S, Zhou H, et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(D1):D92–97.

[27] Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Research. 2020;48(D1):D127–D131.

[28] Shannon P, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.

[29] Chin CH, Chen S-H, Wu -H-H, et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11.

[30] Yao Y, Zhang T, Qi L, et al. Integrated analysis of co-expression and ceRNA network identifies five lncRNAs as prognostic markers for breast cancer. J Cell Mol Med. 2019;23(12):8410–8419.

[31] Langfelder P, Zhang B, Horvath S. Defining clusters from a hierarchical cluster tree: the dynamic tree cut package for R. Bioinformatics. 2008;24(5):719–720.

[32] Zhang T, Jiang M, Chen L, et al. Prediction of gene phenotypes based on GO and KEGG pathway enrichment scores. BioMed Research International. 2013;2013:870795.

[33] Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287.

[34] Luo W, Brouwer C. Pathview: an R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics. 2013;29(14):1830–1831.

[35] Rich JT, Neely JG, Paniello RC, et al. A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg. 2010;143(3):331–336.

[36] Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452–463.

[37] Jiang MC, Ni JJ, Cui WY, et al. Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019;9(7):1354–1366.

[38] Brisotto G, Guerrieri Roberto, Colizzi Francesca, et al. Long noncoding RNAs as innovative urinary diagnostic biomarkers. Methods Mol Biol. 2021;2292:73–94.
[39] Shi T, Gao G, Cao Y. Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. Dis Markers. 2016;2016:9085195.

[40] Walker C, Mojares E, Del Río Hernández A. Role of extracellular matrix in development and cancer progression. Int J Mol Sci. 2018;19(10):3028.

[41] Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, et al. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11:5120.

[42] Rabinovitch RC, Samborska B, Faubert B, et al. AMPK maintains cellular metabolic homeostasis through regulation of mitochondrial reactive oxygen species. Cell Rep. 2017;21(1):1–9.

[43] Garcia D, Shaw RJ. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell. 2017;66(6):789–800.

[44] Lin B, White JT, Ferguson C, et al. PART-1: a novel human prostate-specific, androgen-regulated gene that maps to chromosome 5q12. Cancer Res. 2000;60(4):858–863.

[45] Kang M, Ren M, Li Y, et al. Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA. J Exp Clin Cancer Res. 2018;37(1):171.

[46] Lou T, Ke K, Zhang L, et al. PART1 facilitates the malignant progression of colorectal cancer via miR-150-5p/LRG1 axis. J Cell Biochem. 2020;121(10):4271–4281.

[47] Chen Y, Zhou X, Huang C, et al. LncRNA PART1 promotes cell proliferation and progression in non-small-cell lung cancer cells via sponging miR-17-5p. J Cell Biochem. 2021;122(3–4):315–325.

[48] Zhao X, Hong Y, Cheng Q, et al. PART1 exerts tumor-suppressive functions in tongue squamous cell carcinoma via miR-503-5p. Onco Targets Ther. 2020;13:9977–9989.

[49] Song Y, Pan Y, Liu J. Functional analysis of lncRNAs based on competitive endogenous RNA in tongue squamous cell carcinoma. PeerJ. 2019;7:e6991.

[50] Zhu K, Miao C, Tian Y, et al. LncRNA MIR4435-2HG promoted clear cell renal cell carcinoma malignant progression via miR-513a-5p/KLF6 axis. J Cell Mol Med. 2020;24(17):10013–10026.

[51] Wang H, Wu M, Lu Y, et al. LncRNA MIR4435-2HG targets desmoplakin and promotes growth and metastasis of gastric cancer by activating Wnt/β-catenin signaling. Aging (Albany NY). 2019;11(17):6657–6673.

[52] Dong X, Yang Z, Yang H, et al. Long non-coding RNA MIR4435-2HG promotes colorectal cancer proliferation and metastasis through miR-206/YAP1 axis. Front Oncol. 2020;10:160.

[53] Xu H, Zhang B, Yang Y, et al. LncRNA MIR4435-2HG potentiates the proliferation and invasion of glioblastoma cells via modulating miR-1224-5p/TGFBR2 axis. J Cell Mol Med. 2020;24(11):6362–6372.

[54] Zhu L, Wang A, Gao M, et al. LncRNA MIR4435-2HG triggers ovarian cancer progression by regulating miR-128-3p/CKD14 axis. Cancer Cell Int. 2020;20(1):145.

[55] Qian H, Chen L, Huang J, et al. The lncRNA MIR4435-2HG promotes lung cancer progression by activating β-catenin signalling. Journal of Molecular Medicine (Berlin, Germany). 2018;96(8):753–764.

[56] Bai Y, Lin H, Chen J, et al. Identification of prognostic glycolysis-related lncRNA signature in tumor immune microenvironment of hepatocellular carcinoma. Front Mol Biosci. 2021;8:645084.

[57] Wang S, Chen X, Qiao T. Long noncoding RNA MIR44352HG promotes the progression of head and neck squamous cell carcinoma by regulating the miR3835p/RBM3 axis. Oncol Rep. 2021;45(6). DOI:10.3892/or.2021.8050

[58] Hanahan D, Weinberg R. A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.

[59] Liang X, Wu Z, Shen S, et al. LINC01980 facilitates esophageal squamous cell carcinoma progression via regulation of miR-190a-5p/MYO5A pathway. Arch Biochem Biophys. 2020;686:108371.

[60] Zhang S, Liang Y, Wu Y, et al. Upregulation of a novel lncRNA LINC01980 promotes tumor growth of esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2019;513(1):73–80.

[61] Zang Y, Yi Q, Pan J, et al. LINC01980 stimulates the progression of hepatocellular carcinoma via downregulating caspase 9. Journal of B.U.ON.: official journal of the Balkan Union of Oncology. 2020;25(3):1395–1403.